Haryana to get mega Cancer Hospital in MAMC, Agroha zimbabwestar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zimbabwestar.com Daily Mail and Mail on Sunday newspapers.
In what can be termed as a dream come true for the people of Haryana who had to travel to Delhi and Chandigarh for Cancer treatment, Maharaja Agrasen Medical College Agroha (Hisar) will soon have a mega cancer hospital equipped with all modern facilities.
Here are the top stocks that are likely to be in focus today:
Reliance Industries: The company, in a late night filing, said that it has begun the process of carving out the O2C business into an independent subsidiary. The process for seeking approvals is likely to be completed by Q2FY22. The reorganisation of the O2C business will result in no change in the company s shareholding.
Jindal Power: The firm announced the appointment of former bureaucrat Anil Kumar Jha as its Chairman. A veteran of the mining industry, Jha is former chairman of Coal India Limited, JPL said in a statement.
Stocks in news: RIL, Airtel, HDFC Bank, Vedanta, UPL, Info Edge, Bharat Forge
Stocks to watch today on February 23: RIL, Airtel, HDFC Bank, Vedanta, UPL, Info Edge, Bharat Forge among others are the top stocks to watch out for in Tuesday s trading session
BusinessToday.In | February 23, 2021 | Updated 09:40 IST
Stocks to watch today on February 23
Stocks to watch today: Here is a list of top stocks that are likely to be in focus in Tuesday s trading session based on latest developments.
Reliance Industries: The company said on February 23 that it is carving out its Oil-to-Chemicals (O2C) business into an independent subsidiary. RIL said it will retain 100 percent management control of the new subsidiary. In a notification to exchanges, RIL said that the promoter group will continue to hold a 49.14 percent stake in the O2C business after the reorganisation and that the process will result in no change in shareholding of the company.
Ajanta Pharma - Q3 FY21 Result Update - YES Securities
Posted On:
(Rating: BUY, TP: Rs2,130, Upside: 18.4%)
- Revised FY21 domestic growth guidance from -5% to +2% to +3% growth along with sustained 32% margin
- US business will continue to clock 18-20% growth on FY21 base driven by 7-8 approvals and ~5% R&D spending.
- Revise FY21/22/23 EPS on back of strong beat by 17%/6%/6% and TP to Rs2,130 based on unchanged 25x FY23 EPS. AJP continues to be amongst Top BUYs.
Shares of AJANTA PHARMA LTD. was last trading in BSE at Rs.1799.05 as compared to the previous close of Rs. 1746.15. The total number of shares traded during the day was 32166 in over 2268 trades.